Product
Linaclotide
Aliases
[9-L-tyrosine]heat-stable enterotoxin (Escherichia coli)-(6-19)-peptide, Linzess, MD-1100
Name
Linzess
INN Name
linaclotide
FDA Approved
Yes
6 clinical trials
1 organization
14 indications
1 document
Indication
Chronic ConstipationIndication
ConstipationIndication
Diabetes MellitusIndication
Colorectal AdenomaIndication
Stage 0 Colorectal Cancer AJCC v8Indication
Colorectal CancerIndication
Stage IIIA Colorectal Cancer AJCC v8Indication
Colorectal Cancer, Stage IIIBIndication
Functional ConstipationIndication
Chronic Idiopathic ConstipationIndication
Barrett's EsophagusIndication
Gastroesophageal Reflux DiseaseIndication
Neoplasm, Digestive System, MalignantClinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide in Pediatric Participants, Ages 6 to 17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) and of Linaclotide Versus Placebo in Pediatric Participants With Functional Constipation (FC)Status: Active (not recruiting), Estimated PCD: 2024-05-20
Clinical trial
Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over TrialStatus: Active (not recruiting), Estimated PCD: 2024-10-30
Clinical trial
Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Less Than 2 Years of Age With Functional Constipation (FC).Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment ExtensionStatus: Recruiting, Estimated PCD: 2025-08-15
Clinical trial
Pilot Study of GCC Agonists to Identify a Cyclic-GMP Signal in Duodenal Tissue of VolunteersStatus: Recruiting, Estimated PCD: 2025-02-01
Document
DailyMed Label: LinzessOrganization
Allergan, Inc.